# Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine

> **NCT00825058** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 317 (actual)

## Conditions studied

- Major Depressive Disorders

## Interventions

- **DRUG:** amibegron (SR58611A)
- **DRUG:** placebo
- **DRUG:** paroxetine

## Key facts

- **NCT ID:** NCT00825058
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2004-05
- **Final completion:** 2004-10
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2009-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00825058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00825058, "Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00825058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*